Aardvark Therapeutics (AARD) Enterprise Value (2024 - 2026)
Aardvark Therapeutics (AARD) posted Enterprise Value of -$120.0 million for Q1 2026, down 9.03% sequentially from -$110.0 million in Q4 2025, and up 56.54% YoY from -$76.6 million in Q1 2025.
Aardvark Therapeutics (AARD) Enterprise Value (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Enterprise Value for 3 years, with the latest figure at -$120.0 million in Q1 2026.
- Quarterly Enterprise Value rose 56.54% year-over-year to -$120.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$120.0 million (up 56.54% YoY) and the FY2025 annual result came in at -$110.0 million, down 49.37% from the prior year.
- Enterprise Value slipped to -$120.0 million in Q1 2026 per AARD's latest filing, from -$110.0 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$73.7 million in Q4 2024 and troughed at -$276.1 million in Q1 2025.
- A 3-year average of -$175.1 million and a median of -$166.7 million in 2025 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2025 and 2026: Enterprise Value plunged 49.37% in 2025, then surged 56.54% in 2026.
- Over 3 years, Enterprise Value stood at -$73.7 million in 2024, then slumped by 49.37% to -$110.0 million in 2025, then declined by 9.03% to -$120.0 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$120.0 million, -$110.0 million, and -$213.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 2.12 Bn |
| 10 | Aardvark Therapeutics | 142.55 Mn | 68.63 Mn | - | -73.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -73.92 Mn |
| Mar 31, 2026 | -119.96 Mn |
| Dec 31, 2025 | -110.03 Mn |
| Sep 30, 2025 | -213.47 Mn |
| Jun 30, 2025 | -257.62 Mn |
| Mar 31, 2025 | -276.06 Mn |
| Dec 31, 2024 | -73.66 Mn |